Maria Kelly, NP
Acute Care · Missoula, MTNPI 1205394764
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.2% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 28.9% of the total.
Across 62 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$279
- Johnson & Johnson$219
- Otsuka America Pharmaceutical, Inc.$166
- Teva Pharmaceuticals USA, Inc.$147
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$61
- Lundbeck LLC$61
- plus $33 from 1 others
What the payments were for
- Food & beverage$89192%
- Education$758%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 17 | $279 |
| Johnson & Johnson | 12 | $219 |
| Otsuka America Pharmaceutical, Inc. | 10 | $166 |
| Teva Pharmaceuticals USA, Inc. | 14 | $147 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $61 |
| Lundbeck LLC | 3 | $61 |
| Braeburn Inc. | 2 | $33 |
How this compares
Too few acute care providers in Montanato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clozapine | 19 | $1,944 |
| Olanzapine | 45 | $1,096 |
| Prazosin Hcl | 31 | $702 |
| Aripiprazole | 22 | $460 |
| Haloperidol | 15 | $381 |
| Divalproex Sodium | 12 | $279 |
| Propranolol Hcl | 25 | $258 |
| Divalproex Sodium ErDivalproex Sodium | 17 | $233 |
| Hydroxyzine Pamoate | 27 | $216 |
| Lithium Carbonate ErLithium Carbonate | 21 | $188 |
| Lamotrigine | 27 | $181 |
| Trazodone Hcl | 31 | $170 |
| Risperidone | 17 | $129 |
| Quetiapine Fumarate | 35 | $128 |
| Duloxetine Hcl | 18 | $113 |
Paid to pharmacies, not to this prescriber.
Other acute care in Missoula
- Matthew ShryockMissoula$457
- Kim PowellMissoula$126
- Barbara McGeeMissoula$24
- Joy RodriguezBillings$3K
- Rebecca KochnerBillings$2K
- Sarah-Anne GallowayGreat Falls$303
- Ashley CampbellGreat Falls$242
- Pamela SmithKalispell$173
- Peter MolnarGreat Falls$155
- Kendall BabbKalispell$118
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.